Compare SOTK & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | SERA |
|---|---|---|
| Founded | 1975 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 75.2M |
| IPO Year | 1995 | 2021 |
| Metric | SOTK | SERA |
|---|---|---|
| Price | $5.17 | $2.16 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 52.4K | 30.7K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | 32.32 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $20,909,315.00 | $81,000.00 |
| Revenue This Year | $4.02 | $554.81 |
| Revenue Next Year | $10.95 | $517.27 |
| P/E Ratio | $105.00 | ★ N/A |
| Revenue Growth | 1.97 | ★ 5.19 |
| 52 Week Low | $3.23 | $1.56 |
| 52 Week High | $6.24 | $3.95 |
| Indicator | SOTK | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 47.03 | 52.76 |
| Support Level | $5.01 | $1.68 |
| Resistance Level | $5.72 | $2.40 |
| Average True Range (ATR) | 0.39 | 0.19 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 17.89 | 55.39 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.